


AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~Compounds A~~ A compound of the general formula 1,



General Formula 1

wherein:

Py represents quinolin-4-yl which is unsubstituted or mono- or disubstituted independently with lower alkyl or aryl-lower alkyl in the positions 2, 6 or 8; [1,8]naphthyridin-4-yl which is unsubstituted or monosubstituted in position 7 with lower alkyl; pyridin-4-yl which is unsubstituted or disubstituted in positions 2 and 6, ~~whereby the~~ wherein a substituent in position 2 is R⁵R⁶N-, lower alkyl, aryl-lower alkyl, or (*E*)-2-aryl-ethen-1-yl, and ~~the~~ a substituent in position 6 is hydrogen or lower alkyl;

X is absent or represents a methylene group;

R¹ represents hydrogen; lower alkyl; aryl; aryl-lower alkyl; lower alkyl disubstituted with aryl; or lower alkyl disubstituted with aryl and additionally substituted at a carbon atom bearing an aryl group with OH, CN, or CONR⁷R⁸;

R² forms together with R³ a five-, six-, or seven-membered ring containing the nitrogen atom to which R² is attached as a ring atom and in which case R⁴ represents hydrogen; or

R² forms together with R⁴ a five-, six-, or seven-membered ring containing the nitrogen atom to which R² is attached as a ring atom and in which case R³ represents hydrogen;

the rings formed between R² and R³ or between R² and R⁴ are unsubstituted or monosubstituted with lower alkyl, aryl, aryl-lower alkyl, hydroxy, or aryloxy;

R⁵ and R⁶ independently represent hydrogen; lower alkyl; aryl; aryl-lower alkyl; or form together with the nitrogen atom to which they are attached a pyrrolidine, piperidine, or morpholine ring;

R^7 and R^8 independently represent hydrogen; lower alkyl; aryl; aryl-lower alkyl; or form together with the nitrogen atom to which they are attached a pyrrolidine, piperidine, or morpholine ring;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates; ~~as well as~~ and their pharmaceutically acceptable salts, solvent complexes, and morphological forms.

2. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein R^3 forms together with R^2 an unsubstituted five-, six-, or seven-membered ring containing the nitrogen atom to which R^2 is attached as a ring atom, ~~and R^4 is hydrogen and Py, X, and R^1 have the meaning given in general formula 1 above.~~

3. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein R^4 forms together with R^2 an unsubstituted five-, six-, or seven-membered ring containing the nitrogen atom to which R^2 is attached as a ring atom, ~~and R^3 is hydrogen and Py, X, and R^1 have the meaning given in general formula 1 above.~~

4. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein Py represents quinolin-4-yl mono- or disubstituted independently with lower alkyl or aryl-lower alkyl in the positions 2 or 8, ~~and R^1 , R^2 , R^3 , R^4 , and X have the meaning given in general formula 1 above.~~

5. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein Py represents pyridin-4-yl substituted in position 2 with R^5R^6N -, wherein R^5 represents lower alkyl and R^6 represents aryl-lower alkyl, ~~and R^1 , R^2 , R^3 , R^4 , and X have the meaning given in general formula 1 above.~~

6. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein Py represents pyridin-4-yl substituted in position 2 with R^5R^6N -, wherein R^6 represents hydrogen ~~and R^1 , R^2 , R^3 , R^4 , R^5 , and X have the meaning given in general formula 1 above.~~

7. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein X is absent and R^1 , R^2 , R^3 , R^4 , and Py have the meaning given in general formula 1 above.

8. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein Py represents pyridin-4-yl disubstituted in position 2 and 6 with lower-alkyl, and R^1 , R^2 , R^3 , R^4 , and X have the meaning given in general formula 1 above.

9. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein Py represents pyridin-4-yl disubstituted in position 2 with aryl-lower alkyl and in position 6 with lower-alkyl, and R^1 , R^2 , R^3 , R^4 , and X have the meaning given in general formula 1 above.

10. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein R^1 represents lower alkyl disubstituted with aryl and R^2 , R^3 , R^4 , X, and Py have the meaning given in general formula 1 above.

11. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein R^1 represents lower alkyl disubstituted with aryl and additionally substituted at a carbon atom bearing an aryl group with OH, CN, or $CONR^7R^8$, and R^2 , R^3 , R^4 , R^7 , R^8 , X, and Py have the meaning given in general formula 1 above.

12. (Currently amended) ~~Compounds of general formula 1 are the compounds~~ The compound of claim 1, wherein X is absent, R^3 forms together with R^2 an unsubstituted five-, six-, or seven-membered ring containing the nitrogen atom to which R^2 is attached as a ring atom, R^4 is hydrogen, and Py represents quinolin-4-yl mono- or disubstituted independently with lower alkyl or aryl-lower alkyl in the positions 2 or 8, and R^1 has the meaning given in general formula 1 above.

13. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R³ forms together with R² an unsubstituted five-, six-, or seven-membered ring containing the nitrogen atom to which R² is attached as a ring atom, R⁴ is hydrogen, and Py represents pyridin-4-yl substituted in position 2 with R⁵R⁶N-, wherein R⁶ represents aryl-lower alkyl and R⁵ represents lower alkyl, ~~and R¹ has the meaning given in general formula 1 above.~~

14. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R³ forms together with R² an unsubstituted five-, six-, or seven-membered ring containing the nitrogen atom to which R² is attached as a ring atom, R⁴ is hydrogen, and Py represents pyridin-4-yl substituted in position 2 with R⁵R⁶N-, wherein R⁶ represents hydrogen, ~~and R¹, and R⁵ have the meaning given in general formula 1 above.~~

15. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R³ forms together with R² an unsubstituted five-, six-, or seven-membered ring containing the nitrogen atom to which R² is attached as a ring atom, R⁴ is hydrogen, and Py represents pyridin-4-yl disubstituted in position 2 and 6 with lower-alkyl, ~~and R¹ has the meaning given in general formula 1 above.~~

16. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R³ forms together with R² an unsubstituted five-, six-, or seven-membered ring containing the nitrogen atom to which R² is attached as a ring atom, R⁴ is hydrogen, and Py represents pyridin-4-yl disubstituted in position 2 with aryl-lower alkyl and in position 6 with lower-alkyl, ~~and R¹ has the meaning given in general formula 1 above.~~

17. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R³ forms together with R² an unsubstituted five-, six-, or seven-membered ring containing the nitrogen atom to which R² is attached as

a ring atom, R^4 is hydrogen, and R^1 represents lower alkyl disubstituted with aryl, and Py has the meaning given in general formula 1 above.

18. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R^3 forms together with R^2 an unsubstituted five-membered ring containing the nitrogen atom to which R^2 is attached as a ring atom, R^4 is hydrogen, and Py represents quinolin-4-yl monosubstituted with lower alkyl or aryl-lower alkyl in the position 2 and R^1 has the meaning given in general formula 1 above.

19. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R^3 forms together with R^2 an unsubstituted five-membered ring containing the nitrogen atom to which R^2 is attached as a ring atom, R^4 is hydrogen, and Py represents pyridin-4-yl substituted in position 2 with R^5R^6N- , wherein R^6 represents hydrogen and R^5 , and R^6 have the meaning given in general formula 1 above.

20. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R^3 forms together with R^2 an unsubstituted five-membered ring containing the nitrogen atom to which R^2 is attached as a ring atom, R^4 is hydrogen, and Py represents pyridin-4-yl disubstituted in position 2 and 6 with lower-alkyl and R^1 has the meaning given in general formula 1 above.

21. (Currently amended) ~~Compounds of general formula 1 are the compounds~~
The compound of claim 1, wherein X is absent, R^3 forms together with R^2 an unsubstituted five-membered ring containing the nitrogen atom to which R^2 is attached as a ring atom, R^4 is hydrogen, and R^1 represents lower alkyl disubstituted with aryl, and Py has the meaning given in general formula 1 above.

22. (Currently amended) ~~The compound according to any one of claims 1 to 21 that is~~ A compound selected from the group consisting of:

1-(2-Methyl-quinolin-4-yl)-3-pyrrolidin-3-yl-urea;

1-[1-(2,2-Diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;
1-[1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-
urea;
1-(2-Methyl-quinolin-4-yl)-3-(1-phenethyl-pyrrolidin-3-yl)-urea;
1-(2-Methyl-quinolin-4-yl)-3-[1-(3-phenyl-propyl)-pyrrolidin-3-yl]-urea;
1-(2-Methyl-quinolin-4-yl)-3-(1-naphthalen-1-ylmethyl-pyrrolidin-3-yl)-
urea;
1-(2-Methyl-quinolin-4-yl)-3-(1-naphthalen-2-ylmethyl-pyrrolidin-3-yl)-
urea;
1-(1-Biphenyl-4-ylmethyl-pyrrolidin-3-yl)-3-(2-methyl-quinolin-4-yl)-urea;
1-(2-Methyl-quinolin-4-yl)-3-[1-(4-phenyl-cyclohexyl)-pyrrolidin-3-yl]-urea;
1-[(*R*)-1-(1-Methyl-2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-
quinolin-4-yl)-urea;
1-[(*S*)-1-(1-Methyl-2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-
quinolin-4-yl)-urea;
1-[1-(3,3-Diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-
urea;
1-[1-(2,3-Diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-
urea;
1-[1-(2-Hydroxy-2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-
4-yl)-urea;
1-[1-(2,2-Diphenyl-ethyl)-piperidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;
1-[1-(3,3-Diphenyl-propyl)-piperidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;
1-[(*S*)-1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-
yl)-urea;
1-[(*R*)-1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-
4-yl)-urea;
1-[(*S*)-1-(3,3-Diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-
urea;

1-[(*R*)-1-(3,3-Diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;

(*R*)-1-(1-Benzyl-pyrrolidin-3-yl)-3-(2-methyl-quinolin-4-yl)-urea;

(*S*)-1-(1-Benzyl-pyrrolidin-3-yl)-3-(2-methyl-quinolin-4-yl)-urea;

1-(1-Benzyl-pyrrolidin-3-yl)-3-(2-methyl-quinolin-4-yl)-urea;

1-[(*S*)-1-(2-Hydroxy-2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[(*R*)-1-(2-Hydroxy-2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[(*S*)-1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-2-ylmethyl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[(*R*)-1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-2-ylmethyl]-3-(2-methyl-quinolin-4-yl)-urea;

N,N-Diethyl-4-[(*S*)-3-[3-(2-methyl-quinolin-4-yl)-ureido]-pyrrolidin-1-yl]-2,2-diphenyl-butyramide;

N,N-Diethyl-4-[(*R*)-3-[3-(2-methyl-quinolin-4-yl)-ureido]-pyrrolidin-1-yl]-2,2-diphenyl-butyramide;

N,N-Dimethyl-4-[(*S*)-3-[3-(2-methyl-quinolin-4-yl)-ureido]-pyrrolidin-1-yl]-2,2-diphenyl-butyramide;

N,N-Dimethyl-4-[(*R*)-3-[3-(2-methyl-quinolin-4-yl)-ureido]-pyrrolidin-1-yl]-2,2-diphenyl-butyramide;

1-(1-Biphenyl-3-ylmethyl-pyrrolidin-3-yl)-3-(2-methyl-quinolin-4-yl)-urea;

1-[(*S*)-1-Biphenyl-2-ylmethyl-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[(*S*)-1-(3-Cyano-3,3-diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[(*R*)-1-(3-Cyano-3,3-diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[(*S*)-1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-3-yl]-3-(2,6-dimethyl-pyridin-4-yl)-urea;

1-[(*R*)-1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-3-yl]-3-(2,6-dimethyl-pyridin-4-yl)-urea;

1-(2,6-Dimethyl-pyridin-4-yl)-3-[(*S*)-1-(2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-urea;

1-(2,6-Dimethyl-pyridin-4-yl)-3-[(*S*)-1-(2-hydroxy-2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-urea;

1-(2,6-Dimethyl-pyridin-4-yl)-3-[(*R*)-1-(2-hydroxy-2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-urea;

1-(2,6-Dimethyl-pyridin-4-yl)-3-[(*S*)-1-(3,3-diphenyl-propyl)-pyrrolidin-3-yl]-urea;

1-(2,6-Dimethyl-pyridin-4-yl)-3-[(*R*)-1-(3,3-diphenyl-propyl)-pyrrolidin-3-yl]-urea;

1-[(*S*)-1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-3-yl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea;

1-[(*S*)-1-(2,2-Diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea;

1-[(*S*)-1-(3,3-Diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea;

1-[(*S*)-1-(3,3-Diphenyl-propyl)-pyrrolidin-3-yl]-3-[2-methyl-6-((*E*)-styryl)-pyridin-4-yl]-urea;

1-[(*S*)-1-(2,2-Diphenyl-ethyl)-pyrrolidin-3-yl]-3-{2-[(*E*)-2-(4-fluorophenyl)-vinyl]-6-methyl-pyridin-4-yl}-urea;

1-[(*S*)-1-(2,2-Diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-6-phenethyl-pyridin-4-yl)-urea;

1-[(*S*)-1-(1-Benzyl-2-phenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-6-propyl-pyridin-4-yl)-urea;

1-[(*S*)-1-(2,2-Diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methyl-6-propyl-pyridin-4-yl)-urea;

1-[(*S*)-1-(3,3-Diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-methyl-6-propyl-pyridin-4-yl)-urea;

1-[2-(Benzyl-methyl-amino)-pyridin-4-yl]-3-[(S)-1-(2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-urea;

1-[(S)-1-(3,3-Diphenyl-propyl)-pyrrolidin-3-yl]-3-(2-methyl-6-phenethyl-pyridin-4-yl)-urea;

1-[(S)-1-(2,2-Diphenyl-ethyl)-pyrrolidin-3-yl]-3-{2-[2-(4-fluoro-phenyl)-ethyl]-6-methyl-pyridin-4-yl}-urea;

1-[(S)-1-(2,2-Diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-methylamino-pyridin-4-yl)-urea;

1-[(S)-1-(2,2-Diphenyl-ethyl)-pyrrolidin-3-yl]-3-(2-propylamino-pyridin-4-yl)-urea;

1-(2-Cyclopentylamino-pyridin-4-yl)-3-[(S)-1-(2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-urea; and

1-(2-Benzylamino-pyridin-4-yl)-3-[(S)-1-(2,2-diphenyl-ethyl)-pyrrolidin-3-yl]-urea.

23. (Currently amended) ~~Pharmaceutical compositions containing A~~
~~pharmaceutical composition comprising a compound of any one of claims 1 to 22 claim 1~~
~~and usual a pharmaceutically acceptable carrier materials and adjuvants or adjuvant, or both~~
~~for the treatment of disorders which are associated with a dysregulation of urotensin II or~~
~~urotensin II receptors, especially disorders associated with vascular or myocardial~~
~~dysfunction, comprising hypertension, atherosclerosis, angina or myocardial ischemia,~~
~~congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic~~
~~kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia,~~
~~migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic~~
~~nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary~~
~~disease, high altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid~~
~~dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis.~~

24. (Cancelled).

25. (Cancelled).

26. (Cancelled).

27. (Cancelled).

28. (New) The pharmaceutical composition of claim 23 further comprising an additional pharmacologically active compound.

29. (New) The pharmaceutical composition of claim 28, wherein the additional pharmacologically active compound is selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, beta-adrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.

30. (New) A method of preventing or treating a disorder which is associated with a dysregulation of urotensin II or urotensin II receptors, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.

31. (New) The method of claim 30, wherein the disorder is at selected from the group consisting of hypertension, atherosclerosis, angina, myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, and pulmonary fibrosis.

32 (New) A method of preventing or treating a disorder comprising administering to a subject in need thereof a prophylactically or therapeutically effective amount of the compound of claim 1, wherein the disorder is selected from the group consisting of restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia,

shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, seizures, stress, and depression.

33 (New) A method of preventing or treating a disorder, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 23, wherein the disorder is selected from the group consisting of hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis, restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, seizures, stress, and depression.

34. (New) The method of claim 33, wherein the pharmaceutical composition further comprises an additional pharmacologically active compound selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, beta-adrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.